Division of Hematology/Oncology, Department of Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL.
Division of Pulmonary and Critical Care Medicine, Department of Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL.
Hematology Am Soc Hematol Educ Program. 2021 Dec 10;2021(1):478-484. doi: 10.1182/hematology.2021000282.
Chronic thromboembolic pulmonary hypertension (CTEPH) is a rare complication in pulmonary embolism (PE) survivors, characterized by chronic vascular occlusion and pulmonary hypertension. The identification and diagnosis of CTEPH requires a stepwise approach, starting with symptom evaluation, functional evaluation, screening imaging, and progressing to interventional hemodynamic assessment. On the backbone of anticoagulation, CTEPH management necessitates a multidisciplinary approach. Surgical pulmonary thromboendarterectomy (PTE) is the only potentially curative option. In nonoperable disease or residual disease after PTE, interventional balloon pulmonary angioplasty and/or pulmonary-vasodilator therapies can be offered, in collaboration with interventional and vascular pulmonary colleagues. As it is a disease that can cause high morbidity and mortality, CTEPH requires a high index of suspicion to diagnose and treat in patients following PE.
慢性血栓栓塞性肺动脉高压(CTEPH)是肺血栓栓塞症(PE)幸存者的一种罕见并发症,其特征为慢性血管阻塞和肺动脉高压。CTEPH 的识别和诊断需要采用逐步方法,从症状评估、功能评估、筛查影像学开始,然后进行介入性血流动力学评估。在抗凝治疗的基础上,CTEPH 管理需要多学科方法。外科肺动脉血栓内膜切除术(PTE)是唯一有潜在治愈可能的选择。对于无法手术或 PTE 后的残留疾病,可以与介入和血管肺科同事合作,提供介入性球囊肺动脉血管成形术和/或肺血管扩张剂治疗。由于 CTEPH 是一种可导致高发病率和死亡率的疾病,因此需要对 PE 患者进行高度怀疑以诊断和治疗。